Advagene Biopharma Co., Ltd.

Advagene Biopharma Co., Ltd. is a biotechnology company specializing in the research and development of vaccines and immunotherapies. Headquartered in Taipei, Taiwan, and established in 2006, the company focuses primarily on leveraging its proprietary detoxified LT adjuvant platform, a genetic modification of Escherichia coli heat-labile enterotoxin, to enhance the efficacy of vaccine products. Notable development projects include a nasal spray influenza vaccine, allergy vaccines, and immunotherapy targeting COVID-19. Advagene Biopharma's work addresses pressing needs in infectious disease prevention and allergy treatment, positioning it at the intersection of healthcare innovation and public health response. Despite having a lean operational team, the company's activities reflect a strong emphasis on early-stage biologic product innovation, holding multiple patents related to vaccine and immunotherapy technologies. In the broader financial market, Advagene Biopharma serves as a representative of Taiwan’s growing biopharmaceutical sector, providing exposure to advancements in next-generation vaccine delivery and immunological therapies.